OCULAR THERAPEUTIX, INC (OCUL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 49.17M USD | Liabilities, Current |
| Cash and equivalents | 598.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 30.26M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 3.83M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $49.17M | $598.64M | (m) | $30.26M | $3.83M | (m) |
| 2026-03-31 | (m) | $47.68M | $666.70M | (m) | $24.35M | $3.74M | (m) |
| 2025-12-31 | (m) | $50.81M | $737.06M | (m) | $30.65M | $3.56M | (m) |
| 2025-09-30 | (m) | $49.29M | $344.77M | (m) | $30.77M | $3.49M | (m) |
| 2025-06-30 | (m) | $42.93M | $391.13M | (m) | $30.41M | $3.04M | (m) |
| 2025-03-31 | (m) | $37.93M | $349.68M | (m) | $25.22M | $3.27M | (m) |
| 2024-12-31 | (m) | $41.35M | $392.10M | (m) | $32.39M | $3.04M | (m) |
| 2024-09-30 | (m) | $36.36M | $427.22M | (m) | $30.23M | $2.40M | (m) |
| 2024-06-30 | (m) | $29.97M | $459.69M | (m) | $30.23M | $2.55M | (m) |
| 2024-03-31 | (m) | $24.30M | $482.89M | (m) | $26.55M | $2.57M | (m) |
| 2023-12-31 | (m) | $34.90M | $195.81M | (m) | $26.18M | $2.31M | (m) |
| 2023-09-30 | (m) | $35.07M | $110.55M | (m) | $23.59M | $2.26M | (m) |
| 2023-06-30 | (m) | $32.36M | $66.61M | (m) | $27.31M | $2.20M | (m) |
| 2023-03-31 | (m) | $29.71M | $79.03M | (m) | $21.12M | $2.27M | (m) |
| 2022-12-31 | (m) | $31.39M | $102.30M | (m) | $21.32M | $1.97M | (m) |
| 2022-09-30 | (m) | $29.27M | $120.95M | (m) | $19.80M | $1.54M | (m) |
| 2022-06-30 | (m) | $26.11M | $134.54M | (m) | $20.48M | $1.50M | (m) |
| 2022-03-31 | (m) | $23.96M | $145.42M | (m) | $23.21M | $1.36M | (m) |
| 2021-12-31 | (m) | $26.34M | $164.16M | (m) | $21.14M | $1.25M | (m) |
| 2021-09-30 | (m) | $25.16M | $179.28M | (m) | $19.55M | $1.22M | (m) |
| 2021-06-30 | (m) | $21.55M | $191.86M | (m) | $18.73M | $1.11M | (m) |
| 2021-03-31 | (m) | $27.44M | $209.38M | (m) | $13.63M | $1.12M | (m) |
| 2020-12-31 | (m) | $26.66M | $228.06M | (m) | $12.25M | $1.20M | (m) |
| 2020-09-30 | (m) | $22.91M | $70.64M | (m) | $7.78M | $1.15M | (m) |
| 2020-06-30 | (m) | $13.80M | $84.29M | (m) | $2.87M | $1.07M | (m) |
| 2020-03-31 | (m) | $11.11M | $48.15M | (m) | $3.43M | $1.11M | (m) |
| 2019-12-31 | (m) | $12.03M | $54.44M | (m) | $2.55M | $954.00K | (m) |
| 2019-09-30 | (m) | $11.01M | $65.41M | (m) | $1.11M | $895.00K | (m) |
| 2019-06-30 | (m) | $10.13M | $61.77M | (m) | $615.00K | $762.00K | (m) |
| 2019-03-31 | (m) | $8.61M | $76.25M | (m) | $276.00K | $265.00K | (m) |
| 2018-12-31 | (m) | $9.16M | $54.06M | (m) | $201.00K | $217.00K | (m) |
| 2018-09-30 | (m) | $13.41M | $56.86M | (m) | $240.00K | $102.00K | (m) |
| 2018-06-30 | (m) | $11.90M | $56.83M | (m) | $285.00K | $131.00K | (m) |
| 2018-03-31 | (m) | $13.15M | $62.91M | (m) | $170.00K | $139.00K | (m) |
| 2017-12-31 | (m) | $13.43M | $41.54M | (m) | $226.00K | $122.00K | (m) |
| 2017-09-30 | (m) | $10.95M | $51.16M | (m) | $278.00K | $127.00K | (m) |
| 2017-06-30 | (m) | $13.13M | $63.05M | $3.00M | (m) | $90.00K | (m) |
| 2017-03-31 | (m) | $8.66M | $54.68M | $25.70M | (m) | $96.00K | (m) |
| 2016-12-31 | $68.39M | $8.30M | $32.94M | $35.21M | $250.00K | $113.00K | 8.24× |
| 2016-09-30 | (m) | $8.24M | $52.23M | $23.51M | (m) | $126.00K | (m) |
| 2016-06-30 | (m) | $6.42M | $48.17M | $35.72M | (m) | $149.00K | (m) |
| 2016-03-31 | (m) | $6.00M | $46.21M | $49.24M | (m) | $127.00K | (m) |
| 2015-12-31 | $105.26M | $5.38M | $30.78M | $74.28M | $193.00K | $134.00K | 19.57× |
| 2015-09-30 | $113.83M | $11.18M | $41.20M | $72.44M | $189.00K | $147.00K | 10.18× |
| 2015-06-30 | $123.89M | $9.59M | $78.69M | $45.04M | $164.00K | $145.00K | 12.92× |
| 2015-03-31 | $67.78M | $7.23M | $12.52M | $54.90M | $352.00K | $158.00K | 9.38× |
| 2014-12-31 | $75.16M | $5.87M | $37.39M | $37.44M | $329.00K | $133.00K | 12.79× |
| 2014-09-30 | (m) | $3.38M | $80.89M | (m) | $53.00K | $117.00K | (m) |
| 2014-06-30 | (m) | $4.49M | $19.94M | (m) | $60.00K | $109.00K | (m) |
| 2014-03-31 | (m) | (m) | $12.75M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $3.34M | $17.50M | (m) | $250.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | $21.62M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $25.03M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $23.85M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $5.33M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |